Polio endgame: the global introduction of inactivated polio vaccine
- PMID: 25597843
- DOI: 10.1586/14760584.2015.1001750
Polio endgame: the global introduction of inactivated polio vaccine
Abstract
In 2013, the World Health Assembly endorsed a plan that calls for the ultimate withdrawal of oral polio vaccines (OPV) from all immunization programs globally. The withdrawal would begin in a phased manner with removal of the type 2 component of OPV in 2016 through a global switch from trivalent OPV to bivalent OPV (containing only types 1 and 3). To mitigate risks associated with immunity gaps after OPV type 2 withdrawal, the WHO Strategic Advisory Group of Experts has recommended that all 126 OPV-only using countries introduce at least one dose of inactivated polio vaccine into routine immunization programs by end-2015, before the trivalent OPV-bivalent OPV switch. The introduction of inactivated polio vaccine would reduce risks of reintroduction of type 2 poliovirus by providing some level of seroprotection, facilitating interruption of transmission if outbreaks occur, and accelerating eradication by boosting immunity to types 1 and 3 polioviruses.
Keywords: eradication; immunization; inactivated polio vaccine; oral polio vaccine; polio; poliomyelitis.
Similar articles
-
Eradicating polio: how the world's pediatricians can help stop this crippling illness forever.Pediatrics. 2015 Jan;135(1):196-202. doi: 10.1542/peds.2014-3163. Pediatrics. 2015. PMID: 25548328
-
Polio endgame: the global switch from tOPV to bOPV.Expert Rev Vaccines. 2016 Jun;15(6):693-708. doi: 10.1586/14760584.2016.1140041. Epub 2016 Feb 2. Expert Rev Vaccines. 2016. PMID: 26751187 Review.
-
[Polio vaccines, eradication and posterradication].Rev Esp Salud Publica. 2013 Sep-Oct;87(5):497-505. doi: 10.4321/S1135-57272013000500008. Rev Esp Salud Publica. 2013. PMID: 24322286 Spanish.
-
India's Preparedness for Introduction of IPV and Switch from tOPV to bOPV.Indian Pediatr. 2016 Aug 7;53 Suppl 1:S44-S49. Indian Pediatr. 2016. PMID: 27771639
-
Polio eradication: the OPV paradox.Rev Med Virol. 2003 Sep-Oct;13(5):277-91. doi: 10.1002/rmv.401. Rev Med Virol. 2003. PMID: 12931339 Review.
Cited by
-
Safety and immunogenicity of shorter interval schedules of the novel oral poliovirus vaccine type 2 in infants: a phase 3, randomised, controlled, non-inferiority study in the Dominican Republic.Lancet Infect Dis. 2024 Mar;24(3):275-284. doi: 10.1016/S1473-3099(23)00519-4. Epub 2023 Dec 15. Lancet Infect Dis. 2024. PMID: 38109921 Free PMC article. Clinical Trial.
-
Immuno-persistence of the different primary polio vaccine schedules and immunogenicity of the booster dose by sabin inactivated or bivalent oral poliovirus vaccine in children aged 4 years: an open-label, randomised, controlled phase 4 trial in China.Lancet Reg Health West Pac. 2023 Mar 17;34:100725. doi: 10.1016/j.lanwpc.2023.100725. eCollection 2023 May. Lancet Reg Health West Pac. 2023. PMID: 37283972 Free PMC article.
-
Immunogenicity of Catch-Up Immunization with Conventional Inactivated Polio Vaccine among Japanese Adults.Vaccines (Basel). 2022 Dec 15;10(12):2160. doi: 10.3390/vaccines10122160. Vaccines (Basel). 2022. PMID: 36560570 Free PMC article.
-
Anti-bacterial monoclonal antibodies: next generation therapy against superbugs.Appl Microbiol Biotechnol. 2022 Jun;106(11):3957-3972. doi: 10.1007/s00253-022-11989-w. Epub 2022 Jun 1. Appl Microbiol Biotechnol. 2022. PMID: 35648146 Review.
-
The impact of different IPV-OPV sequential immunization programs on hepatitis A and hepatitis B vaccine efficacy.Hum Vaccin Immunother. 2022 Dec 31;18(1):2024063. doi: 10.1080/21645515.2021.2024063. Epub 2022 Jan 19. Hum Vaccin Immunother. 2022. PMID: 35044877 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical